Vasopressin

Evidence Level: L5

Predicted Indications: 2

Vasopressin

Pharmacist Assessment Report

Vasopressin: From an Unspecified Original Indication to Congenital Prothrombin Deficiency

One-Sentence Summary

Vasopressin is a hormone-based injectable marketed in Canada, but the data compiled for this report do not specify its approved indication. The TxGNN model predicts it may be effective for congenital prothrombin deficiency, but there are 0 clinical trials and only 3 loosely related publications (one review and two case reports on other clotting-factor deficiencies), so this remains essentially a model prediction.

Quick Overview

Item	Content
Original Indication	Not specified in the available Health Canada licence data
Predicted New Indication	Congenital prothrombin deficiency
TxGNN Prediction Score	0.9963
Evidence Level	L5 (no trials; indirect literature only, none on prothrombin deficiency)
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for vasopressin in the data compiled for this report. Based on general pharmacology, vasopressin and its analogue desmopressin (DDAVP) act through V2 receptors to release stored factor VIII and von Willebrand factor from endothelial cells.

That mechanism is relevant to factor VIII and combined factor V/VIII deficiencies, not to prothrombin (factor II) deficiency. No documented mechanism raises prothrombin levels. The very high TxGNN score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The prediction should therefore be treated as a hypothesis with weak mechanistic support.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21115138	2011	Review	Autoimmunity Reviews	Overview of acquired hemophilia A (autoantibodies against factor VIII): diagnosis, causes and treatment options. Not specific to prothrombin deficiency.
2607619	1989	Case report	Rinsho Ketsueki	DDAVP given to a patient with congenital combined factor V and factor VIII deficiency.
1942544	1991	Case report	Rinsho Ketsueki	Cesarean section managed with factor VIII concentrates in a pregnant woman with combined factor V and VIII deficiency.

None of these papers addresses prothrombin (factor II) deficiency directly.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02247938	Vasopressin Injection USP	Not listed	Not listed
02139502	Vasopressin Injection, USP	Not listed	Not listed

Both licences are valid single-ingredient products.

Safety Considerations

Drug Interactions: The interaction screening returned 100 potential interactions. Examples of the main ones, by severity:
- Major: dolasetron, cisapride, papaverine, macimorelin
- Moderate: famotidine, epinephrine, loperamide, chlorpropamide, clarithromycin, levofloxacin, ondansetron, granisetron, palonosetron, promethazine, cilostazol, heparin, and others
- Minor: metronidazole

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score alone. There are no clinical trials, the supporting papers concern other factor deficiencies, and the known mechanism (raising factor VIII and von Willebrand factor) does not apply to prothrombin deficiency.

To proceed, the following is needed:

The approved indications and the package insert warnings and contraindications from Health Canada
Mechanism of action data, and evidence of any effect on prothrombin levels
Preclinical or clinical evidence specific to congenital prothrombin deficiency
A review of the major drug interactions listed above
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.